“Lymphoproliferative skin lesion as a previously unreported adverse event detected in a patient receiving mSTR TB treatment” (2022) Journal of Pharmacovigilance and Drug Research, 3(2), pp. 34–37. doi:10.53411/jpadr.2022.3.2.7.